Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up – Should You Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $16.40, but opened at $17.2950. Hikma Pharmaceuticals shares last traded at $17.2950, with a volume of 167 shares trading hands.

Analyst Ratings Changes

Separately, Barclays downgraded Hikma Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Hikma Pharmaceuticals Trading Up 1.9%

The company has a quick ratio of 0.72, a current ratio of 1.24 and a debt-to-equity ratio of 0.33. The firm’s fifty day moving average is $20.12 and its two-hundred day moving average is $21.41.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.